

DAFTAR PUSTAKA

- Agrawal, S., Zaritsky, J.J., Fornoni, A., Smoyer, W.W. 2018. Dyslipidemia in Nephrotic Syndrome: Mechanisms and Treatment. *Nat Rev Nephrol*, vol 14, issue 1, p. 57-70.
- Ahmad, N., and Rajak, D.K. 2017. Assesment of Serum Lipid in Nephrotic Syndrome in Children. *International Journal of Medical and Health Research*, vol 3, issue 3, p. 89-93.
- Ahnadi, C.E., Berthezene, F., Ponsin, G. 1993. Simvastatin-induced Decrease in The Transfer of Cholesterol Esters from High Density Lipoproteins to Very Low and Low Density Lipoproteins in Normolipidemic Subjects. *Atherosclerosis*, vol 99, p. 219-228.
- Akchurin, O., Reidy, K.J. 2015. Genetic Causes of Proteinuria and Nephrotic Syndrome: Impact on Podocyte Pathobiology. *Pediatr Nephrol*, vol 30, p. 221-233.
- Ali, E.M.A., Bushara, H.M.M., Abdelraheem, M.B. 2013. Dyslipidemia among Children with Nephrotic Syndrome in Sudan. *Khartoum Medical Journal*, vol 6, issue 3, p. 915-922.
- Allredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., Williams, B.R. 2013. *Applied Therapeutics: The Clinical Use of Drugs 10th Edition*. Philadelphia: Lippincott Williams & Wilkins, p. 194.
- Armitage, J., Holmes, M.V., Preiss, D. 2019. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events. *Journal of The American College of Cardiology*, vol 73, issue 4, p. 477-487.
- Audard, V., Larousserie, F., Grimbert, P. et al. 2006. Minimal Change Nephrotic Syndrome and Classical Hodgkin's Lymphoma: Report of 21 Cases and Review of The Literature. *Kidney Int*, vol 69, p. 2251-2260.
- Baigent, C. et al. 2011. The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. *Lancet*, vol. 377, p. 2181-2192.
- Bakker, W.W., van Dael, C.M., Pierik, L.J., et al. 2005. Altered Activity of Plasma Hemopexin in Patients with Minimal Change Disease in Relapse. *Pediatr Nephrol*, vol 20, p. 1410-1415.
- Banh, T.H., Hussain-Shamsy, N., Patel, V., et al. 2016. Ethnic Differences in Incidence and Outcomes of Childhood Nephrotic Syndrome. *Clin J Am Soc Nephrol*, vol 11, p. 1760-1768.

- Barrios-González, J., Miranda, R.U. 2010. Biotechnological Production and Applications of Statins. *Appl Microbiol Biotechnol*, vol 85, p. 869-883.
- Barter, P.J., and Kastelein, J.J.P. 2006. Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. *Journal of the American College of Cardiology*, vol 47, p. 492-499.
- Bell, S., Cooney, J., Packard, C.J., Caslake, M.J., Deighan, C.J. 2012. The Effect of Omega-3 Fatty Acids on The Atherogenic Lipoprotein Phenotype in Patients with Nephrotic Range Proteinuria. *Clin Nephrol*, vol. 77, p. 445-453.
- Berg, van den J.G., Weening, J.J. 2004. Role of The Immune System in The Pathogenesis of Idiopathic Nephrotic Syndrome. *Clin Sci*, vol 107, p. 125-136.
- Bhatnagar, D., Durrington, P.N., Kumar, S. et al. 1995. Effect of Treatment with A Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor on Fasting and Postprandial Plasma Lipoproteins and Cholesteryl Ester Transfer Activity in Patients with NIDDM. *Diabetes*, vol 44, p. 460-465.
- Bienias, B., Zajackowska, M., Borzecka, H., Sikora, P., Majewski, M., Ksiazek, E., et al. 2012. Selected Thrombosis and Atherosclerosis Risk Factors in Children with Idiopathic Nephrotic Syndrome. *J Biochem Tech*, vol 3, p. 317-321.
- Boyer, O., Moulder, J.K., Somers, M.J. 2007. Focal and Segmental Glomerulosclerosis in Children: A Longitudinal Assessment. *Pediatr Nephrol*, vol 22, p. 1159-1166.
- Bulich, G., Trujillano, D., Santin, S., Ossowski, S., Mendizabal, S., Fraga, G. et al. 2015. Targeted Next-Generation Sequencing in Steroid-Resistant Nephrotic Syndrome: Mutations in Multiple Glomerular Genes may Influence Disease Severity. *Eur J Hum Genet*, vol 23, p. 1192-1199.
- Buscher, A.K., Weber, S. 2012. Educational Paper: The Podocytopathies. *Eur J Pediatr*, vol 171, p. 1151-1160.
- Bushara, H.M. 2006. *Hyperlipidemia in Children With Nephrotic Syndrome in Khartoum State* [Thesis]. Faculty of Medicine University of Khartoum. Sudan.
- Cabezas, M.C., Verseyden, C., Meijssen, S., Jansen, H., Erkelens, D.W. 2004. Effects of Atorvastatin on the Clearance of Triglyceride-Rich Lipoproteins in Familial Combined Hyperlipidemia. *J Clin Endocrinol Metab*, vol 89, p. 5972-5980.
- Carattino, M.D., Hughey, R.P., Kleyman, T.R. 2008. Proteolytic Processing of the Epithelial Sodium Channel Gamma Subunit Has A Dominant Role in Channel Activation. *J Biol Chem*, vol 283, p 90-95.

- Chanchlani, R., Parekh, R.S. 2016. Ethnic Differences in Childhood Nephrotic Syndrome. *Front Pediatr*, vol 4, p.39.
- Charles, M.A., Kane, J.P. 2012. New Molecular Insights into CETP Structure and Function: A Review. *J Lipid Res*, vol 53, p. 1451-1458.
- Chavan, S., Salunkhe, S., Singh, A., Agarkhedkar, S., Sodal, S., Jadhav, R. 2018. Lipid Profile in Children with Nephrotic Syndrome. *International Journal of Pediatric Research*, vol 5, issue 6, p. 314-319.
- Clement, L.C., Avila-Casado, C., Macé, C., et al. 2011. Podocyte-Secreted Angiopoietin-like-4 Mediates Proteinuria in Glucocorticoid-Sensitive Nephrotic Syndrome. *Nat Med*, vol 17, p. 117-122.
- Crawford, B.D., and Gipson, D.S. 2017. Improving The Evidence of The Management of Childhood Nephrotic Syndrome. *Kidney International*, vol 92, p. 21-23.
- Daugirdas, J.T. 2011. *Handbook of Chronic Kidney Disease Management*. Philadelphia: Lippincott Williams & Wilkins, p. 191-192.
- Dnyanesh, DK., Dnyanesh, S., Shenoy, V. 2014. A Study of Serum Lipids in Nephrotic Syndrome in Children. *IOSR Journal of Dental and Medical Sciences*, vol 13, issue 3, p. 1-6.
- Dong, B., Wu, M., Li, H., Kraemer, F.B., Adeli, K., Seidah, N.G., Park, S.W., Liu, J. 2010. Strong Induction of PCSK9 Gene Expression through HNF1alpha and SREBP2: Mechanism for The Resistance to LDL Cholesterol Lowering Effect of Statins in Dyslipidemic Hamsters. *J Lipid Res*, vol 51, p. 1486-1495.
- Downie, M.L., Gallibois, C., Parekh, R.S., Noone, D.G. 2017. Nephrotic Syndrome in Infants and Children: Pathophysiology and Management. *Paediatrics and International Child Health*, vol 37, issue 4, p. 248-258.
- Dullaart, R.P.F., et al. 1993. Role of Elevated Lecithin:Cholesterol Acyltransferase and Cholesteryl Ester Transfer Protein Activities in Abnormal Proteinuric Patients. *Kidney International*, vol 44, p. 91-97.
- Eiland, L.S., Luttrell, P.K. 2010. Use of Statins for Dyslipidemia in The Pediatric Population. *Journal of Pediatric Pharmacology and Therapeutics*, vol 15, p. 160-172.
- EPOGI. 2011. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents National Heart, Lung, and Blood Institute: Summary Report. *Pediatrics*, vol 128, issue 5, p. 213-256.

- Filippas-Ntekouan, S., Elisaf, M.S. 2016. Pathophysiological Mechanisms of Dyslipidemia in Patients with Nephrotic Syndrome: A Fresh Look. *Hell J Atheroscler*, vol 7, issue 3, p. 102-110.
- Frank, S. Kostner, G. 2012. *Lipoproteins: Role in Health and Diseases*. Croatia: InTech, p. 384.
- Furth, S.L., Arbus, G.S., Hogg, R., et al. 2003. Varicella Vaccination in Children with Nephrotic Syndrome: A Report of The Southwest Pediatric Nephrology Study Group. *J Pediatr*, vol 142, p. 145-148.
- Gallon, L., Leventhal, J., Skaro, A., et al. 2012. Resolution of Recurrent Focal Segmental Glomerulosclerosis After Retransplantation. *N Engl J Med*, vol 366, p. 1648-1649.
- Gazzerro, P., Proto, M.C., Gangemi, G., Malfitano, A.M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., Bifulco, M. 2012. Pharmacological Actions of Statins: A Critical Appraisal in The Management of Cancer. *Pharmacol. Rev*, vol 64, p. 102-146.
- Gheith, O.A. et al. 2002. Impact of Treatment of Dyslipidemia on Renal Function, Fat Deposits and Scarring in Patients with Persistent Nephrotic Syndrome. *Nephron*, vol. 91, p. 612-619.
- Gibson, K. L., Hansrivijit, P., Ferris, M. E. 2016. Emerging Agents for The Management of Nephrotic Syndrome: Progress to Date. *Pediatric Drugs*, vol 18, issue 1, p. 25-29.
- Gipson, D.S., Massengill, S.F., Yao, L., et al. 2009. Management of Childhood Onset Nephrotic Syndrome. *Pediatrics*, vol 124, p. 747-757.
- Gipson, D.S., Troost, J.P., Lafayette, R.A., et al. 2016. Complete Remission in The Nephrotic Syndrome Study Network. *Clin J Am Soc Nephrol*, vol 11, p. 81-89.
- Goff, L.W., Guerin, M., Chapman, M.J. 2004. Pharmacological Modulation of Cholesteryl Ester Transfer Protein, A New Therapeutic Target in Atherogenic Dyslipidemia. *Pharmacol Ther*, vol 101, p. 17-38.
- Greenbaum, L.A., Benndorf, R., Smoyer, W.E. 2012. Childhood Nephrotic Syndrome: Current and Future Therapies. *Nat Rev Nephrol*, vol 8, issue 8, p. 445-458.
- Grundy, S.M. 2014. Statins: Definitive Translational Research. *Mol Med*, vol 20, issue 2, p. 20-23.
- Guerin, M., Dolphin, P.J., Talussot, C. et al. 1995. Pravastatin Modulates Cholesteryl Ester Transfer from HDL to ApoB-containing Lipoproteins and Lipoprotein Subspecies

- Profile in Familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol*, vol 15, p. 1359-1368.
- Guerin, M., Lassel, T.S., Goff L.W. et al. 2000. Action of Atorvastatin in Combined Hyperlipidemia: Preferential Reduction of Cholesteryl Ester Transfer from HDL to VLDL1 Particles. *Arterioscler Thromb Vasc Biol*, vol 20, p. 189-197.
- Gwee, A., Rimer, R., Marks, M. 2015. *Paediatric Handbook 9th Edition*. UK: Wiley & Sons Ltd., p. 133.
- Haan, W., Hoogt, C.C., Westerterp, M. et al. 2008. Atorvastatin Increases HDL Cholesterol by Reducing CETP Expression in Cholesterol-Fed APOE*3-Leiden CETP Mice. *Atherosclerosis*, vol 197, p. 57-63.
- Haas, M.E., Levenson, A.E., Sun, X., Liao, W.H., Rutkowski, J.M., de Ferranti, S.D., Schumacher, V.A., Scherer, P.E., Salant, D.J., Biddinger, S.B. 2016. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. *Circulation*, vol 134, p. 61-72.
- Hall, G. Gbadegesin, R.A. 2015. Translating Genetic Findings in Hereditary Nephrotic Syndrome: The Missing Loops. *Am J Physiol Renal Physiol*, vol 309, issue 1, p. 24-28.
- Hari, P., Khandelwal, P., Satpathy, A. et al. 2018. Effect of Atorvastatin on Dyslipidemia and Carotid Intima-Media Thickness in Children with Refractory Nephrotic Syndrome: A Randomized Controlled Trial. *Pediatr Nephrol*, vol 33, issue 12, p. 2299-2309.
- Hatakeyama, K. 2016. CETP Activity: A Link between Lipid Metabolism and Coagulation System. *J Atheroscler Thromb*, vol 23, p. 1144-1146.
- Hay, W.W., Levin, M.J., Deterding, R.R., Abzug, M.J. 2016. *Current Diagnosis & Treatment Pediatrics 23th Edition*. United States: McGraw-Hill Education, p. 719-720.
- Hinkes, B.G., Mucha, B., Vlangos, C.N., Gbadegesin, R., Liu, J., Hasselbacher, K., Hangan, D., Ozaltin, F., Zenker, M., Hildebrandt, F. 2007. Nephrotic Syndrome in The First Year of Life: Two Thirds of Cases are Caused by Mutations in 4 Genes (NPHS1, NPHS2, WT1, and LAMB2). *Pediatrics*, vol 119, p. 907-919.
- Hossain, A., Deb, K.P., Hossain, M.A., Mannan, K.A., Mostafa, G., Hossain, M.M. 2016. Correlation between Serum Cholesterol and Serum Albumin Level in Childhood Nephrotic Syndrome. *Urol Nephrol Open Access J*, vol 3, p. 115-118.

- Jacobson, T.A., Maki, K.C., Orringer, C., Jones, P.H., Kris-Etherton, P., Sikland, G. 2015. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. *Journal of Clinical Lipidology*, vol 9, issue 6, p. 1-122.
- Jin, K., Park, B.S., Kim, Y.W., et al. 2014. Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-Sectional Study. *Am J Kidney Dis*, vol 63, p. 584-589.
- Johnson, R.J., Feehally, J., Floege, J. 2015. *Comprehensive Clinical Nephrology 5th Edition*. Philadelphia: Elsevier Inc., p. 212.
- Kapelle, P.J., Zwang, L., Huisman, M.V., Banga, J.D., Sluiter, W.J., Dallinga-Thie, G.M., Dullaart, R.P. 2009. Atorvastatin Affects Low Density Lipoprotein and Non-High Density Lipoprotein Cholesterol Relations with Apolipoprotein B in Type 2 Diabetes Mellitus: Modification by Triglycerides and Cholesteryl Ester Transfer Protein. *Expert Opin Ther Targets*, vol 13, p. 743-751.
- Kapur, G., Valentini, R.P., Imam, A.A., et al. 2009. Treatment of Severe Edema in Children with Nephrotic Syndrome with Diuretics Alone – A Prospective Study. *Clin J Am Soc Nephrol*, vol 4, p. 907–913.
- Kari, J.A., Tashkandi, M., Medhat, M.A., Khoja, S.O., Ramadan, K.S. 2012. Lipoprotein (a) and Other Dyslipidemia in Saudi Children with Nephrotic Syndrome (SSNS and SRNS). *Journal of Health Science*, vol 2, p. 57-63.
- Kassai, A., Illyes, L., Mirdamadi, H.Z. et al. 2006. The Effect of Atorvastatin Therapy on Lecithin Cholesterol Acyltransferase, Cholesteryl Ester Transfer Protein and The Antioxidant Paraoxonase. *Clin Biochem*, vol 40, p. 1-5.
- Kavalipati, N., Shah, J., Ramakrishan, A., Vasawala, H. 2015. Pleiotropic Effects of Statins. *Indian Journal of Endocrinology and Metabolism*, vol 19, issue 5, p. 554-562.
- Kayes, M.I. 2016. Recent Update in The Management of Childhood Nephrotic Syndrome. *J Bangladesh Coll Phys Surg*, vol 34, p. 26-32.
- Kerlin, B.A., Blatt, N.B., Fuh, B., et al. 2009. Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) Study. *J Pediatr*, vol 155, p. 105-110.
- Kerlin, B.A., Ayoob, R., Smoyer, W.E. 2010. Epidemiology and Pathophysiology of Nephrotic Syndrome-Associated Thromboembolic Disease. *Clin J Am Soc Nephrol*, vol 7, p. 513-520.

- Kerlin, B.A., Haworth, K., Smoyer, W.E. 2014. Venous Thromboembolism in Pediatric Nephrotic Syndrome. *Pediatr Nephrol*, vol 29, p. 989-997.
- Kidney Disease: Improving Global Outcomes (KDIGO). 2012. Clinical Practice Guideline for Glomerulonephritis. *Kidney Int*, vol 2, p. 139–274.
- Kleta, R., Bockenhauer, D. 2006. Bartter Syndromes and Other Saltlosing Tubulopathies. *Nephron Physiol*, vol 104, p. 73-80.
- Kong, X. et al. 2013. Lipid-Lowering Agents for Nephrotic Syndrome. *Cochrane Database Syst Rev*. 12:CD005425.
- Krishnamurty, C., Rukmani, J., Clarin, D. 2018. Evaluation of Serum Lipid Profile in Children with Nephrotic Syndrome Admitted in Emergency Ward of Government Tirunelveli Medical College and Hospital, India. *Int J Contemp Ped*, vol 5, issue 6, p. 2244-2248.
- Krishnaswamy, D., Indumati, V., Satihkumar, D., Vijay, V., Maharudra, S., Amareshwara, M., et al. 2011. Serum Proteins, Initial and Follow-Up Lipid Profile in Children with Nephrotic Syndrome. *IJABPT*, vol 2, p. 59-63.
- Kumar, V., Abbas, A.K., Aster, J.C. 2013. *Robbins Basic Pathology 9th Edition*. Canada: Elsevier Inc, 517.
- Kwiterovich, P.O. 2010. *The Johns Hopkins Textbook of Dyslipidemia*. Philadelphia: Lippincott Williams & Wilkins, p. 136.
- Langslet, G., Breazna, A., Drogari, E. 2016. A 3-Year Study of Atorvastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia. *Journal of Clinical Lipidology*, vol 10, p. 1153-1162.
- Lauer, R.M., Obarzanek, E., Hunsberger, S.A., et al. 2000. Efficacy and Safety of Lowering Dietary Intake of Total Fat, Saturated Fat, and Cholesterol in Children with Elevated LDL Cholesterol: The Dietary Intervention Study in Children. *The American Journal of Clinical Nutrition*, vol 72, p. 1332-1342.
- Lei, M.A., Zhang, L. et al. 2012. Structural Basis of Transfer between Lipoproteins by Cholesteryl Ester Transfer Protein. *Nat Chem Biol*, vol 8, p. 342-349.
- Lennon, R., Singh, A., Welsh, G.I., et al. 2008. Hemopexin Induces Nephrin-Dependent Reorganization of The Actin Cytoskeleton in Podocytes. *J Am Soc Nephrol*, vol 19, p. 2140-2149.

- Li, X., Le, N.A., Innis-Whitehouse, W. et al. 2000. Lipid and Apolipoprotein Levels and Distribution in Patients with Hypertriglyceridemia: Effect of Triglyceride Reductions with Atorvastatin. *Metabolism*, vol 49, p. 167-177.
- Lwanga, S.K., Lemeshow, S. 1991. *Sample Size Determination in Health Studies: A Practical Manual*. Geneva: World Health Organization.
- Maas, R.J., Deegens, J.K., Wetzels, J.F. 2014. Permeability Factors in Idiopathic Nephrotic Syndrome: Historical Perspectives and Lessons for The Future. *Nephrol Dial Transplant*, vol 29, p. 2207-2216.
- Mahmud, S. Jahan, S. Hossain, M.M. 2011. Hyperlipidemia in Childhood Idiopathic Nephrotic Syndrome during Initial Remission and Relapse. *Mymensingh Med J*, vol 20, issue 3, p. 402-406.
- Martín, J., Buchberger, W., Alonso, E., Himmelsbach, M., Aparicio, I. 2011. Comparison of Different Extraction Methods for The Determination of Statin Drugs in Wastewater and River Water by HPLC/Q-TOF-MS. *Talanta*, vol 85, p. 607-615.
- McCaffrey, J., Lennon, R., Webb, N.J. 2016. The Non-Immunosuppressive Management of Childhood Nephrotic Syndrome. *Pediatr Nephrol*, vol 31, p. 1383-1402.
- McCrinkle, B.W., Ose, L., Marais, A.D. 2003. Efficacy and Safety of Atorvastatin in Children and Adolescents with Familial Hypercholesterolemia or Severe Hyperlipidemia: A Multicenter, Randomized, Placebo-Controlled Trial. *J Pediatr*, vol 142, p. 74-80.
- Mekahli, D., Liutkus, A., Ranchin, B., et al. 2009. Long-Term Outcome of Idiopathic Steroid-Resistant Nephrotic Syndrome: A Multicenter Study. *Pediatr Nephrol*, vol 24, issue 8, p. 1525-1532.
- Moulin, P., Appel, G.B., Ginsberg, H.N., Tall, A.R. 1992. Increased Concentration of Plasma Cholesteryl Ester Transfer Protein in Nephrotic Syndrome: Role in Dyslipidemia. *J Lipid Res*, vol 33, p. 1817-1822.
- Nakanishi, K., Iijima, K., Ishikura, K., et al. 2013. Two-Year Outcome of The ISKDC Regimen and Frequent-Relapsing Risk in Children with Idiopathic Nephrotic Syndrome. *Clin J Am Soc Nephrol*, vol 8, issue 5, p. 756-762.
- Nilawati, G.A.P. 2012. Profil Sindrom Nefrotik pada Ruang Perawatan Anak RSUP Sanglah Denpasar. *Sari Pediatri*, vol 14, issue 4, p. 269-272.
- Noone, D.G., Lijima, K., Parekh, R. 2018. Idiopathic Nephrotic Syndrome in Children. *Lancet*, vol 392, p. 61-74.

- Nourbakhsh, N., Mak, R.H. 2017. Steroid-Resistant Nephrotic Syndrome: Past and Current Perspectives. *Pediatric Health, Medicine, and Therapeutics*, vol 8, p. 29-37.
- Parmar, B. 2017. New Frontiers in Nephrotic Syndrome in Children. *Acad J Ped Neonatol*, vol 5, issue 4, p. 1-4.
- Prelog, M., Schonlaub, J., Zimmerhackl, L.B. 2011. Aciclovir and Varicella-Zoster-Immunoglobulin in Solid-Organ Transplant Recipients. *Pediatr Nephrol*, vol 26, p. 663-673.
- Raghow, R. 2017. Statins Redux: A Re-assessment of How Statins Lower Plasma Cholesterol. *World J. Diabetes*, vol 8, p. 230-234.
- Reiner, Z., et al. 2011. ESC/EAS Guidelines for The Management of Dyslipidaemias: The Task Force for The Management of Dyslipidaemias of The European Society of Cardiology (ESC) and The European Atherosclerosis Society (EAS). *Eur Heart J*, vol 32, p. 1769–1818.
- Rheault, M.N., Zhang, L., Selewski, D.T., et al. 2015. AKI in Children Hospitalized with Nephrotic Syndrome. *Clin J Am Soc Nephrol*, vol 11, p. 2110-2118.
- Saito, T. 2004. Refractory Nephrotic Syndrome. *Nihon Rinsho Japanese Journal of Clinical Medicine*, vol. 62, issue 10, p. 1794.1799.
- Saleem, M.A. 2013. New Developments in Steroid-Resistant Nephrotic Syndrome. *Pediatr Nephrol*, vol 28, p. 699-709.
- Sarker, M.N., Islam, M., Saad, T., Shoma, F.N., Sharmin, L.S., Khan, H.A., et al. 2012. Risk Factor for Relapse in Childhood Nephrotic Syndrome - A Hospital Based Retrospective Study. *Faridpur Med Coll J*, vol 7, p. 18-22.
- Schrier, R.W. 2015. *Manual of Nephrology 8th Edition*. Philadelphia: Wolter Kluwer Health, p. 24-25.
- Selewski, D.T., Troost, J.P., Massengill, S.F., et al. 2015. The Impact of Disease Duration on Quality of Life in Children with Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortium Study. *Pediatr Nephrol*, vol, 30, p. 1467-1476.
- Shipman, K.E., Strange, R.C., Ramachandran, S. Use of Fibrates in The Metabolic Syndrome: A Review. *World J Diabetes*, vol 7, p. 74-88.
- Sirtori, C.R. 2014. The Pharmacology of Statins. *Pharmacol Res*, vol 88, p. 3-11.

- Sreenivasa, B., Manjunatha, B., Joseph, N. 2016. Comparative Study of Lipid Profile Abnormalities in First Episode and Relapse Cases of Childhood Nephrotic Syndrome. *Int J Contemp Pediatr*, vol 3, issue 4, p. 1297-1300.
- Stender, S., Schuster, H., Barter, P., Watkins, C., Kallend, D., MERCURY I Study Group. 2005. Comparison of Rosuvastatin with Atorvastatin, Simvastatin and Pravastatin in Achieving Cholesterol Goals and Improving Plasma Lipids in Hypercholesterolaemic Patients with or without the Metabolic Syndrome in the MERCURY I Trial. *Diabetes Obes. Metab*, vol 7, p. 430-438.
- Svenningsen, P., Bistrup, C., Friis, U.G., et al. 2009. Plasmin in Nephrotic Urine Activates the Epithelial Sodium Channel. *J Am Soc Nephrol*, vol 20, p. 299-310.
- Taal, M.W., Cherlow, G.M., Marsden, P.A., Skorecki, K., Yu, A.S.L., Brenner, B.M. 2012. *Brenner & Rector's The Kidney 9th Edition*. Philadelphia: Elsevier Inc, p. 1990-1992.
- Teoh, C.W., Robinson, L.A., Noone, D. 2015. Perspectives on Edema in Childhood Nephrotic Syndrome. *Am J Physiol Renal Physiol*, vol 309, p. 575-582.
- Thalgahagoda, R.S., Abeyagunawardena, S., Karunadasa, U. 2017. Managing A Child with Nephrotic Syndrome. *Sri Lanka Journal of Child Health*, vol 46, issue 3, p. 267-272.
- Tiwari, V., Khokhar, M. 2014. Mechanism of Action of Anti-Hypercholesterolemia Drugs and Their Resistance. *Eur J Pharmacol*, vol 741, p. 156-170.
- Trautmann, A., Bodria, M., Ozaltin, F., Gheisari, A., Melk, A., Azocar, M. et al. 2015. Spectrum of Steroid-Resistant and Congenital Nephrotic Syndrome in Children: The PodoNet Registry Cohort. *Clin J Am Soc Nephrol*, vol 10, p. 592-600.
- Trihono, P.P., Alatas, H., Tambunan, T., Pardede, S.O. 2012. *Konsensus Tata Laksana Sindroma Nefrotik Idiopatik pada Anak Edisi Kedua*. Jakarta: UKK Nefrologi IDAI, p. 1-21.
- Turner, N., Lameire, N., Goldsmith, D.J., Winearls, C.G., Himmelfarb, J., Remuzzi, G. 2016. *Oxford Textbook of Clinical Nephrology 4th Edition*. UK: Oxford University Press, p. 2714-2719.
- Ulinski, T., Leroy, S., Dubrel, M., Danon, S., Bensman, A. 2008. High Serological Response to Pneumococcal Vaccine in Nephrotic Children at Disease Onset on High-Dose Prednisone. *Pediatr Nephrol*, vol 23, p. 1107-1113.
- Usui, R., Tsuchiya, Y., Nitta, K., Koike, M. 2018. Efficacy of Semiannual Single Fixed Low-Dose Rituximab Therapy in Steroid-Dependent Minimal Change Nephrotic Syndrome: A Case Series. *Case Rep Nephrol Dial*, vol 8, p. 230-237.

- Uwaezuoke, S.N. 2015. Steroid-Sensitive Nephrotic Syndrome in Children: Triggers of Relapse and Evolving Hypotheses on Pathogenesis. *Ital J Pediatr*, vol 41, issue 19, p. 1-6.
- Vaziri, N.D. 2010. Lipotoxicity and Impaired HDL-Mediated Reverse Cholesterol/Lipid Transport in Chronic Kidney Disease. *J Ren Nutr*, vol 20, p. 35-43.
- Vaziri, N.D. 2014. Role of Dyslipidemia in Impairment of Energy Metabolism, Oxidative Stress, Inflammation and Cardiovascular Disease in Chronic Kidney Disease. *Clin Exp Nephrol*, vol 18, p. 265-268.
- Vaziri, N.D. 2015. HDL Abnormalities in Nephrotic Syndrome and Chronic Kidney Disease. *Nat Rev Nephrol*, vol 12, p. 37-47.
- Vaziri, N.D. 2016. Disorders of Lipid Metabolism in Nephrotic Syndrome: Mechanisms and Consequences. *Kidney Int*, vol 90, issue 1, p. 41-52.
- Vuorio, A., Kuoppala, J., Kovanen, P.T., Humphries, S.E., Tonstad, S., Wiegman, A., Drogari, E. 2014. Statins for Children with Familial Hypercholesterolemia. *Cochrane Database of Systematic Reviews*, 7, CD006401.
- Wada, T., Nangaku, M. 2015. A Circulating Permeability Factor in Focal Segmental Glomerulosclerosis: The Hunt Continues. *Clin Kidney J*, vol 8, p. 708-715.
- Wagner, J. Susan, M. 2016. Pediatric Statin Administration: Navigating a Frontier with Limited Data. *J Pediatr Pharmacol Ther*, vol 21, issue 5, p. 380-403.
- Wang, C., Wang, F., Cao, Q. et al. 2018. Effect and Safety of Combination Lipid-Lowering Therapies Based on Statin Treatment versus Statin Monotherapies on Patients with High Risk of Cardiovascular Events. *Aging Medicine*, vol 1, issue 2, p. 176-184.
- Whalen, K. 2015. *Lippincott Illustrated Reviews: Pharmacology 6th Edition*. Philadelphia: Lippincott Williams & Wilkins, p. 328.
- Wharram, B.L., Goyal, M., Wiggins, J.E., et al. 2005. Podocyte Depletion Causes Glomerulosclerosis: Diphtheria Toxin-induced Podocyte Depletion in Rats Expressing Human Diphtheria Toxin Receptor Transgene. *J Am Soc Nephrol*, vol 16, p. 2941-2952.
- Wijk, J.P., Buirma, R., van Tol, A. et al. 2005. Effects of Increasing Doses of Simvastatin on Fasting Lipoprotein Subfractions, and The Effect of High-Dose Simvastatin on Postprandial Chylomicron Remnant Clearance in Normotriglyceridemic Patients with Premature Coronary Sclerosis. *Atherosclerosis*, vol 178, p. 147-155.

- Yamashita, S., Ohama, T., Nishida, M. et al. 2010. Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions. *J Atheroscler Thromb*, vol 17, p. 436-451.
- Yousefichaijan, P., Rezagholizamenjany, M., Rafiei, F., Arjmand, A., Tayebi, S. 2018. Nephrotic Syndrome Outcome in Children: An Epidemiological Study. *J Compr Ped*, vol 9, issue 4, p. 1-6.
- Yu-Poth, S., Zhao, G., Etherton, T. 1999. Effects of the National Cholesterol Education Program's Step I and Step II Dietary Intervention Programs on Cardiovascular Disease Risk Factors: A Meta-Analysis. *Am J Clin Nutr*, vol 69, p. 632-646.
- Zhang, C., Yao, M., Wang, X. et al. 2007. Effect of Hypoalbuminemia on The Increased Serum Cholesteryl Ester Transfer Protein Concentration in Children with Idiopathic Nephrotic Syndrome. *Clin Biochem*, vol 40, p. 869-875.
- Zhang, L., Reue, K., Fong, L.G. et al. 2012. Feedback Regulation of Cholesterol Uptake by The LXR-IDOL-LDLR Axis. *Arterioscler Thromb Vasc Biol*, vol 32, p. 2541-2546.